Document is current
Any future updates will be listed below
-
Authors
Pan, Darren
Mouhieddine, Tarek H. https://orcid.org/0000-0002-1190-5978
Sheng, Tianxiang
Fu, Weijia
Moshier, Erin
Richter, Joshua https://orcid.org/0000-0002-0274-0585
Parekh, Samir
Jagannath, Sundar https://orcid.org/0000-0003-2934-6518
Chari, Ajai
Rossi, Adriana C.
Sanchez, Larysa J.
Thibaud, Santiago
Rodriguez, Cesar
Cho, Hearn J. https://orcid.org/0000-0003-4481-5757
Richard, Shambavi https://orcid.org/0000-0003-0274-4292
- License Information
-
More Information
Article History
Received: 21 January 2026
Revised: 3 March 2026
Accepted: 9 March 2026
First Online: 30 March 2026
Competing interests
: DP: Research funding from Johnson & Johnson, and consulting activity for Regeneron, Pfizer, and Johnson & Johnson. THM: Advisory board fees for Sanofi. JR: Consultant/advisory board: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini, Speakers Bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies. SP: Consulting: Genentech/Roche, Poseida Therapeutics, AstraZeneca, Karyopharm, Bristol Myers Squibb, Janssen/Johnson & Johnson, advisory board for Grail; research support from Celgene/BMS Corporation, Grail, Caribou, imCORE/Genentech, Janssen/Johnson & Johnson. SJ: Consulting for Janssen Pharmaceuticals, BMS, Caribou Biosciences, Legend Biotech, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Poseida Therapeutics; Advisory board for Janssen Pharmaceuticals, BMS, GSK; Data Safety Monitoring Board for Janssen Pharmaceuticals, Sanofi, Genmab. A. Chari has received research funding from Janssen, and he reported consulting activity for Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme. ACR: Consulting for Johnson & Johnson, Adaptive, BMS, Sanofi. LJS: Consulting/advisory board for Janssen Pharmaceuticals. CR: Advisory board for Janssen Pharmaceuticals, Takeda Pharmaceuticals, BMS, Amgen, Karyopharm Therapeutics. HJC: Employment: The Multiple Myeloma Research Foundation, Research funding: Genentech/Roche, BMS, Takeda. The remaining authors declare no relevant competing financial interests.
